Vancomycin-resistant Staphylococcus aureus
A strain of Staphylococcus aureus resistant to vancomycin
Vancomycin-resistant Staphylococcus aureus (VRSA) is a strain of the bacterium Staphylococcus aureus that has developed resistance to the antibiotic vancomycin. This resistance poses significant challenges in the treatment of infections caused by this bacterium.
History[edit | edit source]
The first case of VRSA was reported in 2002 in the United States. The emergence of VRSA is a result of the bacterium acquiring the vanA gene from vancomycin-resistant enterococci (VRE), which confers high-level resistance to vancomycin.
Mechanism of resistance[edit | edit source]
VRSA acquires resistance through the horizontal transfer of the vanA gene cluster, which alters the target site of vancomycin, reducing its binding affinity. This genetic exchange typically occurs in environments where both VRE and S. aureus are present, such as in hospitals.
Clinical significance[edit | edit source]
Infections caused by VRSA are difficult to treat due to limited antibiotic options. VRSA infections can lead to severe outcomes, especially in immunocompromised patients. The resistance to vancomycin necessitates the use of alternative antibiotics, such as linezolid or daptomycin, which may have their own limitations and side effects.
Prevention and control[edit | edit source]
Preventing the spread of VRSA involves strict infection control measures in healthcare settings, including hand hygiene, contact precautions, and surveillance cultures. Reducing the use of vancomycin and other antibiotics can also help prevent the development of resistance.
Research and future directions[edit | edit source]
Ongoing research aims to develop new antibiotics and alternative therapies to combat VRSA. Efforts are also focused on understanding the genetic mechanisms of resistance and the epidemiology of VRSA to better control its spread.
Related pages[edit | edit source]
References[edit | edit source]
Images[edit | edit source]
Vancomycin-intermediate Staphylococcus aureus (VISA)
3D structure of Rifampicin
Staphylococcus aureus on blood agar
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
